(firstQuint)Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma.

 The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line.

 In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.

.

 Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma@highlight

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

